High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the optimal treatment for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). HDT, however, is often reserved for relatively younger patients due to limited data in older adults. We treated 53 patients aged 60 years and older (median age 62 years, range 60.3-67.7 years) with HDT and ASCT for NHL at our centers. Forty-four patients (83%) had aggressive histology, 75% had chemosensitive disease and all had failed anthracycline therapy. Conditioning regimens included busulfan, melphalan, and thiotepa (45%); cyclophosphamide (CY), etoposide (VP-16), and total body irradiation (TBI) (30%); CY and TBI (15%); and other regimens (10%). Estimated 4-year overall survival (OS), progression-free survival, and treatment-related mortality (TRM) were 33%, 24% and 22%, respectively. A multivariable analysis demonstrated that patients with chemosensitive disease (P = 0.03) and р3 prior regimens (P = 0.03) had superior survival. Four-year OS in patients with chemosensitive disease was 39% vs 15% in patients with chemoresistant disease. Reduced TRM was associated with the CY, VP-16 and TBI regimen (P = 0.02). HDT therapy with ASCT may result in prolonged survival and potential cure for about a quarter of elderly patients, and for almost 40% with chemosensitive disease. Optimal conditioning regimen selection may further improve outcome by reducing TRM. Age alone should not be used to exclude patients from receiving myeloablative therapy with ASCT. Over 55 000 patients are diagnosed with non-Hodgkin's lymphoma (NHL) each year in the United States, with over 60% of these cases arising in persons over 60 years of age. 1 NHL is also one of the few malignancies that is increasing in incidence at a rate of 3-4% per year with the greatest increase in patients over 60 years old.
Over 55 000 patients are diagnosed with non-Hodgkin's lymphoma (NHL) each year in the United States, with over 60% of these cases arising in persons over 60 years of age. 1 NHL is also one of the few malignancies that is increasing in incidence at a rate of 3-4% per year with the greatest increase in patients over 60 years old. 2 This cohort of older adults with NHL will be further augmented by the increase in the number of people over 60 from 12% today to a projected 20% of the US population by the year 2030. 3 Presently, an otherwise healthy 60 or 70 year old has a life expectancy of over 83 years, as reflected in this rise in the fraction of older adults. 4 Previous investigators have demonstrated that elderly patients with advanced aggressive NHL benefit from standard full-dose CHOP chemotherapy rather than a dosereduced version, although still less than one-third are cured with such primary treatment. 5 At the time of relapse, highdose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become the standard of care in younger patients, resulting in 20-50% long-term diseasefree survival (DFS). [6] [7] [8] [9] [10] [11] Many clinicians, however, are reluctant to subject adults over the age of 60 to HDT for relapsed NHL because limited data are available on the efficacy of such therapy in this age group and because of concerns regarding toxicity. [12] [13] [14] [15] We evaluated our experience in treating NHL patients over 60 years of age with HDT and ASCT. This report represents, to our knowledge, the largest series published to date describing in detail the outcome of such patients.
Patients and methods

Patients
All patients with NHL that had reached their 60th birthday by the time they received ASCT were identified from the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) computerized database. Clinical and research records of the identified patients were reviewed. All patients provided informed consent for treatment on transplant protocols approved by the appropriate institutional review boards. In addition, separate institutional approval was obtained to retrospectively gather data from patient records and databases.
Study variables
The specific variables evaluated included: age at transplant, histology, presence of B symptoms, bulk of disease at transplant, Ann Arbor stage, number of extranodal sites, number of prior regimens, prior anthracycline exposure, prior cisplatin therapy, sensitivity to chemotherapy at the time of transplant, prior radiotherapy, time from initial diagnosis to transplant, conditioning regimen and stem cell source. Histology was defined by the Revised European American classification of Lymphoid neoplasms (REAL) wherever possible and otherwise by the Working Formulation. 16 Patients with small lymphocytic, mucosa-associated (MALT) or follicular histology were categorized as having 'indolent lymphoma' whereas other histologic entities were considered 'aggressive'. Tumor bulk was defined by the greatest long-axis diameter of the largest tumor mass by computerized tomography or physical examination and categorized as Ͻ5 cm, 5-10 cm, or Ͼ10 cm in size. A prior regimen was defined as one or more cycles of specific chemotherapy or radiotherapy. Chemotherapy utilized to mobilize stem cells was not included as a regimen for this analysis. Patients were considered to have 'chemosensitive disease' if they had achieved a partial response (PR) or complete response (CR) with the regimen immediately prior to transplant.
Treatment regimens
Patients were treated with preparatory regimens including: 
Definition of endpoints and statistical analysis
Overall survival (OS) and progression-free survival (PFS) were computed from the date of stem cell infusion using the method of Kaplan and Meier. Treatment-related mortality (TRM) was defined as non-relapse mortality attributable to the effects of the transplant treatment regimen and estimated using a cumulative incidence estimate. 17 Relapse was regarded as a competing risk for TRM. Proportional hazards regression was used to evaluate the association of factors previously listed with the hazard of failure appropriate to each of these endpoints. Two-sided P values associated with regression models were obtained from the Wald test without adjustment for multiple comparisons.
Results
Baseline characteristics
Between January 1979 and January 1999 we treated 53 patients age 60 and older with HDT and ASCT for relapsed or refractory NHL at our centers. Six patients were transplanted before 1991, seven from 1991 to 1993, 24 from 1994 to 1996, and 16 from 1997 to January 1999. Baseline characteristics of this group were recorded and are summarized in Table 1 . In addition, all patients had been previously treated with an anthracycline-containing regimen and 51% had received prior cisplatin-based therapy. All patients had Southwest Oncology Group (SWOG) performance status of 0 or 1, normal baseline hepatic, renal, cardiac and pulmonary function, and were otherwise considered transplant candidates by their treating physician.
Survival outcomes
The 4-year OS was estimated to be 33% and PFS was estimated to be 24% ( , and mobilized peripheral blood stem cell graft 0.77 (95% CI 0.34-1.73). Continuous variables of age at transplant (P = 0.30) and time from diagnosis to transplant (P = 0.16) were not significantly associated with the hazard of death in the univariate models. The date of transplant evaluated at multiple points (1990, 1993, 1995) was also not associated with the hazard of death. A multivariable model identified chemosensitive disease (hazard ratio 0.42, 95% CI 0.02-0.90, P = 0.03) and treatment with three or fewer prior regimens (hazard ratio 0.37, 95% CI 0.14-0.93, P = 0.03) as factors significantly associated the hazard of mortality. The estimate of survival at 4 years was 39% among patients with chemosensitive disease at the time of transplant compared with 15% among patients with resistant disease (Figure 2 ). Survival curves analyzed by preparative regimen and histology are depicted in Figure 3 .
Subset analysis of the 44 patients (83%) with aggressive histology identified two univariate predictors of improved survival: chemosensitivity (HR 0.38, 95% CI 0.17-0.86, P = 0.02) and small (Ͻ5 cm) tumor bulk at the time of transplant (HR 0.38, 95% CI 0.15-1.0, P = 0.05). Kaplan-Meier estimates of 4-year survival in patients with aggressive histology and sensitive disease or small tumor bulk at the time of transplant were 41% and 38%, respectively (Figure 4) . Exposure to a greater number of prior regimens also demonstrated a trend towards poorer outcome in the cohort with aggressive histology (P = 0.07) when evaluated as a continuous variable.
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Treatment-related mortality
TRM was estimated to be 9.4% at 100 days, 17.4% at 1 year and 22.4% at 3 years as depicted in Figure 5 . Five patients died of infections including: Pneumocystis carinii pneumonia (PCP) (at 2.7 (1998) and 10.7 (1999) months), sepsis syndrome (at 2.0 (1998) and 4.9 (1996) months) and cytomegalovirus (CMV) pneumonitis (at 4.1 months (1996)). In addition, three patients died of idiopathic pneumonitis (at 24 days (1988), 1.4 months (1996) and 26.8 months (1991)), one from adult respiratory distress syndrome (at 4.4 months (1998)), and one from hepatic venoocclusive disease (at 2.0 months (1996)). Factors analyzed for potential correlation with TRM are depicted in Table  2 . None of the 16 patients treated with the CY/VP-16/TBI regimen died from transplant-related causes compared with seven of the 24 (29%) patients treated with the BuMelTT regimen (P = 0.02, log-rank test) and three of 13 patients treated with other regimens (P = 0.05, log-rank test). Receiving prior mediastinal radiation was also associated with a higher TRM (P = 0.03, log-rank test). Adjusted comparisons taking into account potential confounders of these factors could not be performed given the relatively small number of TRM events.
Discussion
NHL in older adults continues to represent a challenge for clinicians. Only recently has the recommended treatment for primary aggressive NHL in elderly patients shifted from less-intensive therapy to anthracycline-containing regimens. 5, 18 Despite CHOP-like initial therapy most older adults will eventually succumb to relapse. Many physicians, however, remain reluctant to utilize the potentially curative approach of HDT and ASCT for relapsed lymphoma due to limited published data in treating an older population with this approach. This reluctance has been reinforced by studies looking at younger cohorts that suggested a direct correlation of age with TRM. 12, 13 These series implicated higher rates and severities of common transplant-related complications such as veno-occlusive disease, idiopathic pneumonitis or infections as the reason for the poorer out- come compared to younger individuals. Neither study, though, demonstrated a correlation of relapse with increasing age, suggesting that TRM may be the main hurdle to overcome in older adults. Unfortunately, these series had Evaluated as a continuous variable. BuMelTT = busulfan, melphalan, and thiotepa; CY/VP-16/TBI = cyclophosphamide, etoposide, fractionated total body irradiation; Other = other regimens. Attenuated dosing = dose reduction from the standard conditioning regimen typically used to treat adults under age 60.
few patients over age 60 and did not focus on patients with NHL. This inadequacy of available data in the older age group of NHL patients has resulted in hesitance to commonly offer HDT and ASCT to adults over 60 to 65 years of age at many centers, including our own. Our study was designed to better define the outcomes as well as the factors predictive of TRM and survival for NHL patients 60 years of age and older treated with HDT and ASCT. The median age of the patients in our series (62 years) is approximately 20 years older than most series of high-dose NHL patients (35-45 years) and is more representative of the population as a whole that is afflicted with lymphoma. 6, 12, [19] [20] [21] [22] Since all patients had relapsed or refractory disease, the estimated 4-year OS and PFS of 33% and 24%, respectively, suggests that a significant proportion of older patients benefited from this aggressive intervention compared to historical non-transplant series. 6, 23, 24, 25 Not surprisingly, the factors most associated with favorable outcome by multivariable analysis in this older cohort, namely chemosensitivity and fewer prior regimens, have also been identified in cohorts of younger patients undergoing HDT for NHL. 10, 26 With nearly 40% of our patients with chemosensitive disease estimated to be alive at 4 years, this study further delineates the specific patient group that may benefit most from aggressive treatment. A myeloablative approach is even more meaningful in patients with aggressive histology, where well-designed randomized trials have demonstrated the efficacy of HDT with ASCT in younger adults with sensitive relapse. 6 In our series it appeared that a significant proportion of the 44 patients with aggressive histologies probably benefited from this intensive therapy. These outcomes are especially notable for those patients with aggressive histology and Bone Marrow Transplantation chemotherapy-responsive disease or Ͻ5 cm of bulk at the time of transplant having an approximately 40% estimated 4-year OS. It remains unclear whether additional factors that were regarded as not being correlated with survival are truly unrelated to outcome or simply failed to achieve statistical significance due to lack of power related to the small number of events.
One of the most striking findings of this series was the considerable 3-year estimate of TRM at 22%. In addition, over half of these deaths occurred more than 100 days post transplant and were equally divided between infectious and non-infectious causes. Three of five infectious deaths occurred between 3 and 11 months post ASCT, potentially suggesting a protracted time to immune reconstitution in older adults. The major lethal direct organ toxicity was pulmonary, with fatal respiratory events occurring up to 27 months following ASCT. Previous authors have hypothesized that the apparent increased susceptibility of normal organs with increasing age to chemotherapeutic agents may be multi-factorial with diminished organ function, altered pharmacokinetics or less effective tissue repair mechanisms all playing a role. [27] [28] [29] Interestingly, patients receiving an attenuated conditioning regimen did not suffer a significantly lower TRM than those who received full doses, possibly reflecting an increasing heterogeneity in patient tolerance to HDT with increasing age rather than a true lack of a dose-toxicity relationship. 27, 29 This lack of significant correlation of TRM with dose could also be explained by both a tendency of clinicians to employ attenuated regimens with 'sicker' patients or simply a lack of statistical power. As in previous series there appeared to be an unadjusted correlation of prior mediastinal radiation with TRM in this group of older patients. 30 In contrast, we were not able to demonstrate any increased toxicity in older patients receiving TBI-based regimens. 14 In fact, patients receiving CY/VP-16/TBI were more likely to have a lower TRM than those who received BuMelTT or other regimens. One must, however, interpret any factors associated with TRM with some caution. For example, we were unable to adequately adjust our analysis for the common practice of preferentially employing chemotherapy-only regimens for patients with prior dose-limiting radiotherapy due to sample size. The major hindrance to a more rigorous examination of TRM was the limited number of events observed which inhibited our ability to fit regression models with multiple explanatory variables and limited the power to detect statistically significant differences.
To overcome this notable TRM it may be possible to specifically design regimens that result in less toxicity by individualizing dosing or by utilizing approaches that depend less on agents with potential variability in absorption, distribution, metabolism, and excretion. At our center we are evaluating the use of myeloablative targeted radioimmunotherapy using patient-specific dosing with the goal of reducing normal organ toxicities while preserving efficacy in older adults with relapsed NHL. One also could hypothesize that outcomes may be further improved in this group by prolonged post-transplant monitoring and antibiotic prophylaxis. At the present time, however, our series suggests that by selecting patients with chemosensitive or low bulk disease HDT can afford prolonged survival and potential cure to approximately 40% of older adults with relapsed NHL. The demography of NHL continues to shift with an increasing majority of cases occurring in adults over 60 years of age. There appears to be no reason to deny potentially curative HDT with ASCT to these older patients strictly on the basis of age, although efforts to diminish the TRM deserve emphasis in this patient population.
